IP Library Granted Patent US 9,282,761
Granted Patent B2
US 9,282,761 · App. 12/598,509 · Granted Mar 15, 2016

Bacteria isolated from fresh honey or the honey producing tract of honey bees

Inventors: Tobias Olofsson (Raa, SE); Alejandra Vasquez (Raa, SE)
A23L1/3014A23K1/009A61K35/644A61K35/745A61K35/747C12R1/01C12R1/225A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,282,761
App. No.
12/598,509
Granted
Mar 15, 2016
Kind
B2
Abstract

The invention relates to new isolated Lactobacillus and Bifidobacterium strains which have been isolated from fresh honey having a water content above 18% by weight or from the honey producing tract of at least one bee. The bacterial strains have unique properties rendering them useful in many products such as in food and beverage products, feed products and medica products.

Claims (11)

1. A composition comprising a sugar source and all isolated bacterial strains selected from the group consisting of: Lactobacillus strain Biut2 (LMG P-24094), Lactobacillus strain Hma2 (LMG P-24093), Lactobacillus strain Hma8 (LMG P-24092), Lactobacillus strain Bma5 (LMG P-24090), Lactobacillus strain Hon2 (LMG P-24091), Bifidobacterium strain Bin7 (LMG P-23986), Bifidobacterium strain Hma3 (LMG P-23983), Bifidobacterium strain Bin2 (LMG P-23984), Bifidobacterium strain Bma6 (LMG P-23985), Lactobacillus kunkeei Fhon2 (LMG P-23987), and Hma11 (LMG P-24612), wherein each isolated bacterial strain is present in the composition at a concentration of 10 3 -10 13 cfu/g composition.

2. A pharmaceutical composition comprising the composition according to claim 1 and a pharmaceutically acceptable carrier or diluent.

3. The pharmaceutical composition according to claim 2 , wherein said composition is a suspension, gel, cream, powder or capsule including the pharmaceutical composition of claim 2 .

4. A pharmaceutical product comprising the pharmaceutical composition according to claim 2 , wherein said product is a dressing, bandage or spray.

5. The composition of claim 1 , wherein the sugar source is selected from the group consisting of honey, sugar, fructose, sucrose, dextrine, maltose or glucose.

6. A food or feed product comprising a sugar source and all isolated bacterial strains selected from the group consisting of: Lactobacillus strain Biut2 (LMG P-24094), Lactobacillus strain Hma2 (LMG P-24093), Lactobacillus strain Hma8 (LMG P-24092), Lactobacillus strain Bma5 (LMG P-24090), Lactobacillus strain Hon2 (LMG P-24091), Bifidobacterium strain Bin7 (LMG P-23986), Bifidobacterium strain Hma3 (LMG P-23983), Bifidobacterium strain Bin2 (LMG P-23984), Bifidobacterium strain Bma6 (LMG P-23985), Lactobacillus kunkeei Fhon2 (LMG P-23987), and Hma11 (LMG P-24612), wherein each isolated bacterial strain is present in the composition at a concentration of 10 3 -10 13 cfu/g composition.

7. A bee feed product comprising all isolated bacterial strains selected from the group consisting of: Lactobacillus strain Biut2 (LMG P-24094), Lactobacillus strain Hma2 (LMG P-24093), Lactobacillus strain Hma8 (LMG P-24092), Lactobacillus strain Bma5 (LMG P-24090), Lactobacillus strain Hon2 (LMG P-24091), Bifidobacterium strain Bin7 (LMG P-23986), Bifidobacterium strain Hma3 (LMG P-23983), Bifidobacterium strain Bin2 (LMG P-23984), Bifidobacterium strain Bma6 (LMG P-23985) and Lactobacillus kunkeei Fhon2 (LMG P-23987), and Hma11 (LMG P-24612), wherein

each isolated bacterial strain is present in the composition at a concentration of 10 3 -10 13 cfu/g composition;

the strain has the ability to inhibit growth of food spoilage and pathogenic microorganisms; and

the strain has the ability to be viable for at least 8 days in a 65% by weight sugar solution.

8. The bee feed product according to claim 7 , wherein the strain has the ability to be viable for at least 8 days in a 70% by weight sugar solution.

Priority Claims (1)
SE 0701050 · May 3, 2007 · national
Continuity (2)
Provisional Application 60916809 · May 9, 2007
Related Publication 20100086528A1 · Apr 8, 2010